BDNF and myeloid sarcoma: For example, several studies have shown that fingolimod [25], the first approved oral drug for MS, glatiramer acetate [26,27,28] and laquinimod [29,30] exert their beneficial effect in treating relapsing remitting MS (RRMS) by increasing BDNF levels.